Virax Biolabs Group Limited
NASDAQ: VRAX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- James Foster
- Employees
- 17
- Headquarters
- London, United Kingdom
- IPO year
- 2022
- Market cap
- $573.1K
- Website
- https://viraxbiolabs.com
Loading VRAX…
Loading profile data…Frequently asked questions about VRAX
What does Virax Biolabs Group Limited (VRAX) do?
Virax Biolabs Group Limited is a biotechnology firm that specializes in the sale, distribution, and promotion of diagnostic testing kits, medical technology, and personal protective equipment (PPE). Its offerings are designed to aid in the prophylaxis, identification, diagnosis, and management of risks associated with viral illnesses within the...
Where does VRAX trade?
Virax Biolabs Group Limited (VRAX) trades on the NASDAQ Capital Market.
What sector is VRAX in?
Virax Biolabs Group Limited (VRAX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Virax Biolabs Group Limited?
James Foster is the chief executive officer of Virax Biolabs Group Limited (VRAX).
Where is Virax Biolabs Group Limited headquartered?
Virax Biolabs Group Limited is headquartered in United Kingdom.
Does VRAX pay a dividend?
Virax Biolabs Group Limited (VRAX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VRAX go public?
Virax Biolabs Group Limited (VRAX) completed its initial public offering in 2022.